Evidence map›Paper›PMID 38806495›Full record

ArticleTranslational psychiatry2024

Mice with deficiency in Pcdh15, a gene associated with bipolar disorders, exhibit significantly elevated diurnal amplitudes of locomotion and body temperature.

Daisuke Mori, Chihiro Inami, Ryosuke Ikeda, Masahito Sawahata, Shinji Urata, Sho T Yamaguchi, Yohei Kobayashi, Kosuke Fujita, Yuko Arioka, Hiroki Okumura and 16 more

Abstract read
In one paragraph

Article in Translational psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Daisuke Mori *Department of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan. d-mori@med.nagoya-u.ac.jp.ORCID 0000-0002-9072-2546
Chihiro Inami *Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan.
Ryosuke IkedaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Masahito SawahataDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan.
Shinji UrataDepartment of Otolaryngology, Graduate School of Medicine, The University of Tokyo, Tokyo Pref., Japan.
Sho T YamaguchiDepartment of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.
Yohei KobayashiSumitomo Pharma Co., Ltd., Osaka City, Osaka Pref., Japan.
Kosuke FujitaDepartment of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Yuko AriokaDepartment of Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0002-1792-8812
Hiroki OkumuraDepartment of Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Itaru KushimaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-0018-5178
Akiko KodamaDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Toshiaki SuzukiDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-0977-1317
Takashi HiraoDepartment of Psychiatry, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akira YoshimiDivision of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Aichi, Japan.ORCID 0000-0001-6636-7970
Akira SobueDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan.
Takahiro ItoDivision of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Aichi, Japan.
Yukikiro NodaDivision of Clinical Sciences and Neuropsychopharmacology, Meijo University Faculty of Pharmacy, Nagoya, Aichi, Japan.
Hiroyuki MizoguchiDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan.
Taku NagaiDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0001-5050-7748
Kozo KaibuchiDivision of Cell Biology, International Center for Brain Science, Fujita Health University, Toyoake, Aichi, Japan.
Shigeo OkabeDepartment of Cellular Neurobiology, Graduate School of Medicine, The University of Tokyo, Tokyo Pref., Japan.ORCID 0000-0003-1216-8890
Koji NishiguchiDepartment of Ophthalmology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kazuhiko KumeDepartment of Neuropharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Aichi, Japan.ORCID 0000-0003-4232-1657
Kiyofumi YamadaDepartment of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University, Graduate School of Medicine, Nagoya, Aichi, Japan.
Norio OzakiDepartment of Pathophysiology of Mental Disorders, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.ORCID 0000-0002-7360-4898

Funding

Japan Agency for Medical Research and Development (AMED) JP19ak0101113Japan Agency for Medical Research and Development (AMED) JP19ak0101126Japan Agency for Medical Research and Development (AMED) JP19dm0207069Japan Agency for Medical Research and Development (AMED) JP19dm0207075Japan Agency for Medical Research and Development (AMED) JP20dk0307099Japan Agency for Medical Research and Development (AMED) JP20ek0109488Japan Agency for Medical Research and Development (AMED) JP21dk0307103Japan Agency for Medical Research and Development (AMED) JP21wm0425007Japan Agency for Medical Research and Development (AMED) JP22gm1410011Japan Agency for Medical Research and Development (AMED) JP22tm0424222Japan Agency for Medical Research and Development (AMED) JP23ek0109678Japan Agency for Medical Research and Development (AMED) JP23gm1910005MEXT | Japan Society for the Promotion of Science (JSPS) 19K07384MEXT | Japan Society for the Promotion of Science (JSPS) 20K20602MEXT | Japan Society for the Promotion of Science (JSPS) 21H04815MEXT | Japan Society for the Promotion of Science (JSPS) 22K07369
6 · The paper itself

Abstract

Genetic factors significantly affect the pathogenesis of psychiatric disorders. However, the specific pathogenic mechanisms underlying these effects are not fully understood. Recent extensive genomic studies have implicated the protocadherin-related 15 (PCDH15) gene in the onset of psychiatric disorders, such as bipolar disorder (BD). To further investigate the pathogenesis of these psychiatric disorders, we developed a mouse model lacking Pcdh15. Notably, although PCDH15 is primarily identified as the causative gene of Usher syndrome, which presents with visual and auditory impairments, our mice with Pcdh15 homozygous deletion (Pcdh15-null) did not exhibit observable structural abnormalities in either the retina or the inner ear. The Pcdh15-null mice showed very high levels of spontaneous motor activity which was too disturbed to perform standard behavioral testing. However, the Pcdh15 heterozygous deletion mice (Pcdh15-het) exhibited enhanced spontaneous locomotor activity, reduced prepulse inhibition, and diminished cliff avoidance behavior. These observations agreed with the symptoms observed in patients with various psychiatric disorders and several mouse models of psychiatric diseases. Specifically, the hyperactivity may mirror the manic episodes in BD. To obtain a more physiological, long-term quantification of the hyperactive phenotype, we implanted nano tag® sensor chips in the animals, to enable the continuous monitoring of both activity and body temperature. During the light-off period, Pcdh15-null exhibited elevated activity and body temperature compared with wild-type (WT) mice. However, we observed a decreased body temperature during the light-on period. Comprehensive brain activity was visualized using c-Fos mapping, which was assessed during the activity and temperature peak and trough. There was a stark contrast between the distribution of c-Fos expression in Pcdh15-null and WT brains during both the light-on and light-off periods. These results provide valuable insights into the neural basis of the behavioral and thermal characteristics of Pcdh15-deletion mice. Therefore, Pcdh15-deletion mice can be a novel model for BD with mania and other psychiatric disorders, with a strong genetic component that satisfies both construct and surface validity.

Indexed as

Bipolar DisorderBody TemperatureCadherinsDisease Models, AnimalLocomotionMice, KnockoutAnimalsBehavior, AnimalCadherin Related ProteinsCircadian RhythmMaleMiceMice, Inbred C57BLPrepulse InhibitionProtein PrecursorsProtocadherinsCadherin Related ProteinsCadherinsCDHR15 protein, mouseProtein PrecursorsProtocadherinsProto-Oncogene Proteins c-fos

Identifiers

PMID38806495
PMCPMC11133426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.